Implications of the Neuroprotective Effects of Lithium for the Treatment of Bipolar and Neurodegenerative Disorders

Pharmacopsychiatry

Volumn 36, Issue SUPPL. 3, 2003, Pages

  Bauer, M ^a   Alda, M ^b   Priller, J ^a   Young, L T ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Bipolar disorder; Huntington's disease; Lithium; Neurodegeneration; Neuroprotection; Signal transduction

Indexed keywords

CALCIUM; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INOSITOL; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; RAS PROTEIN; STABILIZING AGENT; VALPROIC ACID;

BIPOLAR DISORDER; CLINICAL RESEARCH; COGNITION; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG UPTAKE; ENZYME INHIBITION; EXCITATION; IN VITRO STUDY; LONG TERM CARE; NERVE CELL LESION; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; BIPOLAR DISORDER; GLUCOCORTICOIDS; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; LITHIUM COMPOUNDS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; SIGNAL TRANSDUCTION;

EID: 0347003603     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (73)

1. Altshuler LL, Bartzokis G, Grieder T, Curran J, Jimenez T, Leight K, Wilkins J, Gerner R, Mintz J. An MRI study of temporal lobe structures in men with bipolar disorder or schizophrenia. Biol Psychiatry 2000; 48: 147-162
2. Bezchlibnyk Y, Young LT. The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Can J Psychiatry 2002; 47: 135-148
3. Bown CD, Wang JF and Young LT. Attenuation of NMDA-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers. Neuroscience 2003; 117: 949-955
4. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glykogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 2002; 277: 33791-33798
5. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 1999; 96: 8745-8750
6. Chen B, Dowlatshahi D, MacQueen GM, Wang J, Young LT. Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265
7. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-1330
8. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729-1734
9. Chen RW, Qin ZH, Ren M, Kanai H, Chalecka-Franaszek E, Leeds P, Chuang DM. Regulation of c-Jun N-terminal kinase. p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem 2003; 84: 566-575
10. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-160
11. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789
12. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999; 13: 2905-2927
13. Davis GW, Schuster CM, Goodman CS. Genetic dissection of structural and functional components of synaptic plasticity. III. CREB is necessary for presynaptic functional plasticity. Neuron 1996; 17: 669-679
14. Deisseroth K, Bito H, Tsien RW. Signaling from synapse to nucleus: postsynaptic CREB phosphorylation during multiple forms of hippocampal synaptic plasticity. Neuron 1996; 16: 89-101
15. Denicoff KD, Ali SO, Mirsky AF, Smith-Jackson EE, Leverich GS, Duncan CC, Connell EG, Post RM. Relationship between prior course of illness and neuropsychological functioning in patients with bipolar disorder. J Affect Disord 1999; 56: 67-73
16. Deshauer D, Grof E, Aida M, Grof P. Patterns of DST positivity in remitted affective disorders. Biol Psychiatry 1999; 45: 1023-1029
17. Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA 1998; 95: 8363-8367
18. Dong GX, Singh DK, Dendle P, Prasad RM. Regional expression of Bcl-2 mRNA and mitochondrial cytochrome c release after experimental brain injury in the rat. Brain Res 2001; 903: 45-52
19. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 488: 13-828
20. Drevets WC, Ongur D, Price JL. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol Psychiatry 1998; 3: 220-6, 190-191
21. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 2001; 7: 1321-1327
22. Ferrier IN, Stanton BR, Kelly TP, Scott J. Neuropsychological function in euthymic patients with bipolar disorder. Br J Psychiatry 1999; 175: 246-251
23. Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Muller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997; 43: 151-161
24. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 2001; 78: 1219-1232
25. Grof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to lithium stabilization. The importance of patient selection. Br J Psychiatry 1993; 163 21: 16-19
26. Gyulai L, Bauer M, Bauer MS, García-España F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid cycling bipolar disorder after lithium challenge. Biol Psychiatry 2003; 53: 899-905
27. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53
28. Hashimoto R, Fujimaki K, Jeong MR, Christ L, Chuang DM. Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. FEBS Lett 2003; 538: 145-148
29. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002; 80: 589-597
30. Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang D-M. Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 2003; 117: 55-61
31. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 2002; 43: 1173-1179
32. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-128
33. Kane DJ, Sarafian TA, Anton, Hahn H, Gralla EB, Valentine JS, Ord T, Bredesen DE. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993; 262: 1274-1277
34. Kessing LV. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med 1998; 38: 1027-1038
35. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459
36. Kopnisky KL, Chalecka-Franaszek E, Gonzalez-Zulueta M, Chuang DM. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 2003; 116: 425-435
37. Kowaltowski AJ, Vercesi AE, Fiskum G. Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides. Cell Death Differ 2000; 7: 903-910
38. MacQueen GM, Grof P, Aida M, Marriott M, Young LT, Duffy A. Backward masking task performance in affected versus unaffected children of parents with lithium responsive bipolar disorder. Submitted.
39. Manji HK, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 2002; 7 (Suppl 1): S46-56
40. Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. Br J Psychiatry 2001; 178 (Suppl 41): 107-119
41. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 578-593
42. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A Gray N, Zarate CA Jr, Charney DS. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-742
43. Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet 2002; 359: 241-247
44. Nemeth ZH, Deitch EA, Szabo C, Fekete Z, Hauser CJ, Hasko G. Lithium induces NF-kappa B activation and interleukin-8 production in human intestinal epithelial cells. J Biol Chem 2002; 277: 7713-7719
45. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998; 9: 2081-2084
46. Nonaka S, Hough CJ, Chuang D. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 1998; 95: 2642-2647
47. Nonaka S, Katsube N, Chuang DM. Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J Pharmacol Exp Ther 1998; 286: 39-47
48. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290-13295
49. Ozaki N, Chuang DM. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 1997; 69: 2336-2344
50. Passmore M, Garnham J, Duffy A, MacDougall M, Munro A, Slaney C, Teehan A, Alda M. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipol Disord 2003; 5: 110-114
51. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789-813
52. Phiel CJ, Wilson CA, Lee VM-Y, Klein PS. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 2003; 423: 435-439
53. Pilcher HR. Drug research: the ups and downs of lithium. Nature 2003; 425: 118-120
54. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic response to carbamazepine. Psychiatr Res 1987; 21: 71-83
55. Post RM, Weiss SRB. Neurobiological models of recurrence in mood disorder. In: Charney DS, Nestler EJ, Bunney BS, eds. Neurobiology of Mental Illness New York: Oxford University Press, 1999: 365-384
56. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001; 49: 741-752
57. Ren M, Senatorov W, Chen R-W, Chuang D-M. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci USA 2003; 100: 6210-6215
58. Ross EM. Signal sorting and amplification through G protein-coupled receptors. Neuron 1989; 3: 141-152
59. Rubinsztein JS, Michael A, Paykel ES, Sahakian BJ. Cognitive impairment in bipolar affective disorder. Psychol Med 2000; 30: 1025-1036
60. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000; 57: 925-935
61. Silva AJ, Kogan JH, Frankland PW, Kida S. CREB and memory. Annu Rev Neurosci 1998; 21: 127-148
62. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668
63. Strakowski SM, DelBello MP, Adler C, Cecil DM, Sax KW. Neuroimaging in bipolar disorder. Bipol Disord 2000; 2: 148-164
64. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54: 37-42
65. Tham A, Engelbrektson K, Mathe AA, Johnson L, Olsson E, Aberg-Wistedt A. Impaired neuropsychological performance in euthymic with recurring mood disorders. J Clin Psychiatry 1997; 58: 26-29
66. vanGorp WG, Altshuler L, Theberge DC, Wilkins J, Dixon W. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. Arch Gen Psychiatry 1998; 55: 41-46
67. Walton MR, Dragunow I. Is CREB a key to neuronal survival? Trends Neurosci 2000; 23: 48-53
68. Wang JF, Li PP, Warsh JJ, Young LT. Signal transduction abnormalities in bipolar disorder. In: Young LT, Joffe RT, eds. Bipolar disorder: biological models and their clinical application New York: Marcel Dekker, Inc, 1997: 41-79
69. Wei H, Qin Z-H, Senatorov W, Wei W, Wang Y, Qian Y, Chuang D-M. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001; 106: 603-612
70. Young LT, Li PP, Kish SJ, Warsh JJ. Cerebral cortex beta-adrenoceptor binding in bipolar affective disorder. J Affect Disord 1994; 30: 89-92
71. Young LT, Joffe RT. Bipolar disorder: biological models and their clinical application. New York, NY: Marcel Dekker, 1997
72. Yuan P, Chen G, Manji HK. Lithium activates the c-Jun NH2-terminal kinases in vitro and in the CNS in vivo. J Neurochem 1999; 73: 2299-2309
73. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001; 276: 31674-31683